Jane Street
ALDX icon

Jane Street’s Aldeyra Therapeutics ALDX Stock Holding History

Jane Street’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2K Sell
10,400
-95,900
-90% -$165K ﹤0.01% 11182
2026
Q1 		$180K Buy
106,300
+49,100
+86% +$215K ﹤0.01% 10253
2025
Q4 		$296K Buy
57,200
+23,000
+67% +$118K ﹤0.01% 8866
2025
Q3 		$179K Buy
34,200
+7,600
+29% +$39.6K ﹤0.01% 9761
2025
Q2 		$102K Buy
+26,600
New +$68.8K ﹤0.01% 8945
2023
Q3 		– Sell
-14,800
Closed -$124K – 8548
2023
Q2 		$124K Buy
+14,800
New +$146K ﹤0.01% 7909
2022
Q4 		– Sell
-41,200
Closed -$220K – 9049
2022
Q3 		$220K Buy
+41,200
New +$247K ﹤0.01% 8023
2022
Q2 		– Sell
-22,700
Closed -$101K – 9560
2022
Q1 		$101K Sell
22,700
-55,200
-71% -$220K ﹤0.01% 9453
2021
Q4 		$312K Buy
77,900
+55,600
+249% +$424K ﹤0.01% 8091
2021
Q3 		$196K Sell
22,300
-22,200
-50% -$204K ﹤0.01% 8864
2021
Q2 		$504K Buy
44,500
+31,300
+237% +$376K ﹤0.01% 7221
2021
Q1 		$157K Buy
+13,200
New +$152K ﹤0.01% 8437

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Jane Street's ALDX Position: Q2 2026 in Review

Jane Street increased its Aldeyra Therapeutics (ALDX) stake by 42% in Q2 2026, buying an estimated $698K and bringing the position to 1,375,115 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #4556.

Jane Street first reported a position in ALDX in Q3 2017 and has held it in 22 quarters since. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Jane Street held 1,375,115 shares of Aldeyra Therapeutics worth $2.93M as of Q2 2026.
  • Jane Street bought 406,224 Aldeyra Therapeutics shares in Q2 2026, an estimated $698K.
  • Aldeyra Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #4556 holding.
  • Jane Street first reported a position in Aldeyra Therapeutics in Q3 2017 and has held it in 22 quarters since.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.